As it transitions into a clinical-stage company, genetic therapy startup Ensoma is leaving behind half of its employees. CEO Jim Burns confirmed to Endpoints News that only 37 workers will remain with the company.
As it transitions into a clinical-stage company, genetic therapy startup Ensoma is leaving behind half of its employees. CEO Jim Burns confirmed to Endpoints News that only 37 workers will remain with the company.